Medherant’s testosterone TEPI Patch has been well-tolerated and has demonstrated excellent wearability.
10th April 2024
General News
25th March 2024
Coventry, UK (25 March 2024): Medherant Limited (“Medherant”) announces that it has entered into a Development Collaboration Agreement with Bayer for the development of a transdermal patch product for delivery of an a
General News